BPC-157

BPC-157 is a synthetic pentadecapeptide, Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, corresponding to a stable fragment of body protection compound isolated from human gastric juice. Its defining pharmaceutical property is stability in gastric acid — it remains intact for more than 24 hours in the gastric environment, which is why an oral route is viable where most peptides would be hydrolysed.

It was first described in the literature in 1993 and has since accumulated over 100 preclinical studies. Human data remains minimal: as of early 2026 only three published pilot studies exist, and a Phase I trial registered in 2015 that enrolled 42 subjects was cancelled without publishing results.

Regulatory status is restrictive. The FDA has not approved it for human use and classified it in 2023 as a Category 2 bulk drug substance, excluding it from compounding pharmacies. WADA prohibited it in 2022 under S0 Unapproved Substances, and it is banned by the UFC, NFL, NCAA, NHL, MLB, NAIA and PGA. It is not legal for sale as a drug, food or dietary supplement in the US.

Pharmacokinetically it is short-lived: half-life under 30 minutes, hepatic metabolism, renal excretion, detectable in urine for up to 4 days.

BPC-157 is amplificatory rather than initiatory. The central mechanism is upregulation of VEGFR2 expression without a corresponding rise in VEGF-A itself: receptor density increases, so existing angiogenic signalling at the injury site produces a larger response. VEGFR2 activation drives the Akt–eNOS pathway and nitric oxide production, giving vasodilation and neovascularisation of damaged tissue. The practical corollary is that BPC-157 requires an active injury signal to act on.

Cell migration and adhesion proceed through the FAK–paxillin cascade, allowing reparative cells to move into and anchor within damaged tissue. Fibroblast activity rises, increasing collagen production and matrix remodelling. In tendon fibroblasts it upregulates growth hormone receptor expression with downstream JAK2 signalling, sensitising healing tendon to circulating GH.

Anti-inflammatory action is via decreased COX-2 gene expression and reduced IL-6 and TNF-alpha, limiting excessive tissue damage while preserving the macrophage and neutrophil recruitment needed for debris clearance. ERK1/2 activation contributes to proliferation and migration; in wound models this pathway underlies accelerated granulation tissue formation, re-epithelialisation, dermal remodelling and higher collagen deposition.

Additional reported systemic mechanisms include modulation of the nitric oxide system producing bidirectional blood pressure normalisation — pressor in hypotension, vasodilatory in hypertension — and elevation of central dopamine and serotonin, proposed as the basis for analgesia and for protection against the extrapyramidal effects of dopamine antagonists.

Gastric stability exceeding 24 hours distinguishes it from most peptides and underpins the oral route.

BPC-157 acts at several points of the repair cascade simultaneously. In tendon it promotes fibroblast outgrowth, increases cell survival under oxidative stress and enhances migration to injury sites, accelerating healing of transected tendon and tendon-to-bone integration; a medial collateral ligament model showed reduced post-injury instability and contracture. Muscle models show regeneration with improved structure, function and biomechanics after both direct trauma and systemic insult. Bone healing accelerates via osteoblast activity, with one nonunion model reporting results comparable to autologous bone grafting. Injected into scarred tissue it reduces existing fibrosis rather than merely preventing new scar.

In the gastrointestinal tract it is cytoprotective: it interferes with ulcerogenic pathways, accelerates rebuilding of gastric mucosa, protects against NSAID-induced lesions, restores damaged epithelium and improves colonic healing in colitis and inflammatory bowel models. Because it also alters central neurotransmitter balance, it is one of the compounds examined through the gut–brain axis.

Cutaneous models, including alkali burn injury, show accelerated wound closure, granulation tissue formation, re-epithelialisation and collagen deposition. Neurological work reports nerve regeneration in sciatic nerve transection models and neuronal protection from insult.

Systemic effects reported in animal work include bidirectional blood pressure normalisation via the NO system, restoration of normal cardiac rhythm and electrical activity after potassium overdose, protection against hypercalcaemia-related cardiotoxicity, reduction of QT prolongation and catalepsy induced by psychiatric and diabetes medications, reduced lesion volume and mortality after traumatic brain injury, reduced brain damage in multiple sclerosis models, recovery of memory, orientation and motor function after ischaemia–reperfusion injury, and reversal of acute and chronic alcohol toxicity.

On oncology, a 2025 narrative review found that contrary to common assumption BPC-157 inhibits uncontrolled cell proliferation and downregulates VEGF expression in tumour contexts in animal models, appearing to counteract tumour-driven angiogenesis rather than feed it. Human data is described as exceedingly sparse and the authors concluded it should remain investigational. Earlier in vitro work reported apoptotic and pore-forming activity against tumour cells. None of this is a clinical finding, and active malignancy remains a contraindication.

Human timeline data is confined to three small pilot studies and a retrospective review. A retrospective series of 16 patients with chronic knee pain given a single intraarticular injection reported significant pain relief in 14 of 16, lasting 6 to 12 months. A pilot study of 12 women with interstitial cystitis given a single intravesical injection reported complete symptom resolution in 10 of 12. A safety study infused two healthy adults intravenously with up to 20 mg without adverse events or clinically meaningful biomarker changes.

Pharmacokinetics are short: half-life under 30 minutes, hepatic metabolism, renal excretion, urinary detection up to 4 days. Rapid clearance is the practical argument for proximal injection in localised musculoskeletal work.

Aggregated user reports — anecdotal, not published data — describe reduced pain and inflammation within the first 1 to 2 weeks, particularly in acute injury; functional improvement in tendon and ligament injury around weeks 3 to 4; and peak response at weeks 6 to 8. Muscle injuries respond faster, at 2 to 4 weeks, than tendon injuries at 4 to 8 weeks. Chronic or older injuries take 8 to 12 weeks with less predictable outcomes. Users report return to grappling at 3 months and to lifting at 4 months after a near-complete triceps tendon tear run on a BPC-157 and TB-500 protocol, and near-complete resolution of two-decade chronic elbow tendonitis after 8 weeks.

Adverse effects are infrequent and appear dose-dependent and temporary: injection site reactions, mild nausea especially above 500 mcg per day, dizziness and fatigue are most common; anxiety, palpitations, insomnia with late-day dosing, headache and appetite loss are reported less often.

Context matters when setting expectations. The 2025 HSS Journal systematic review of 36 studies found 35 were preclinical and only 1 clinical. The preclinical evidence base is extensive and consistently positive; the human evidence base is promising but extremely thin.

No published dose-finding studies exist for the subcutaneous protocols used in practice. Animal studies used 10 mcg/kg to 10 mg/kg intraperitoneally, subcutaneously, intragastrically or topically, most commonly 10 mcg/kg. Human single doses were far higher: up to 20 mg intravenous, 4000 mcg intraarticular (knee), 10 mg intravesical (bladder). The protocols below reflect usual clinical practice, not trial data.

Standard reconstitution: 5 mg vial with 2 mL bacteriostatic water, yielding 250 mcg per 10 units on an insulin syringe. Larger vials are also in circulation; 10 mg and 20 mg vials are commonly reconstituted with 2.5 mL, giving 4 mg/mL (40 mcg per unit) and 8 mg/mL (80 mcg per unit) respectively — relevant when working near the low end of a 0.3 mL syringe, where small-volume draws lose precision. Store reconstituted vials refrigerated.

Standard protocol: 250 to 500 mcg per day, once or twice daily, morning and/or evening, no fasting required, 4 to 8 weeks for active healing.

Body-weight tiers: under 150 lbs, 200 to 300 mcg daily; 150 to 200 lbs, 300 to 400 mcg daily; over 200 lbs, 400 to 500 mcg daily.

Application tiers: acute injury recovery, 400 to 500 mcg daily for 2 to 4 weeks then reduce; chronic injury support, 250 to 300 mcg daily for 6 to 8 weeks; gut healing, 250 to 500 mcg daily with oral administration preferred; post-surgical recovery, 300 to 400 mcg daily with surgeon approval.

Route: subcutaneous gives slower absorption with reliable systemic distribution, suitable for general repair or multiple simultaneous injury sites and preferred for localised injuries when administered proximally. Intramuscular gives faster absorption and a more pronounced local effect, favoured for acute injury, post-surgical recovery and severe localised inflammation, at the cost of a more difficult and more painful injection.

Site selection: BPC-157 amplifies existing repair signalling at damaged tissue rather than generating it, and with a half-life under 30 minutes proximity determines local concentration. Administer as close to the injury as anatomically appropriate for targeted musculoskeletal work; for multiple injuries or systemic inflammation, abdominal subcutaneous suffices since the peptide still circulates to damaged tissue. Gut-specific indications favour the oral route, where gastric stability exceeding 24 hours delivers it intact to the target tissue.

Cycling: not strictly required. BPC-157 is reactionary — it acts only where an injury signal exists — so the usual approach is continuous use during active healing, 4 to 8 weeks, extendable to 8 to 12 weeks for deeper tissue repair. A structured 8 to 10 weeks on with a 4 to 6 week washout, dosing 5 consecutive days with 2 consecutive rest days, is also used in practice, with continuous 7-day dosing regarded as acceptable over an 8-week cycle. Daily dose is commonly split across 1 to 3 administrations, the usual approach for a peptide with this short a circulating half-life.

Interactions: NSAID data is mixed. Some research indicates BPC-157 counteracts NSAID-induced gut damage, other work suggests NSAIDs may interfere with its regenerative mechanisms. Not a hard contraindication but worth noting. No interaction concerns with GLP-1 agonists or TRT. GH peptides require fasting and BPC-157 does not, so keep them on separate schedules.

BPC-157 was first described in 1993 and has been the subject of over 100 preclinical studies. The evidence base is deep preclinically and extremely thin clinically.

A 2025 systematic review in HSS Journal (Vasireddi et al., 2025) assessed 36 studies in orthopaedic sports medicine: 35 preclinical, 1 human. It corroborated the proposed mechanisms — VEGFR2 upregulation with Akt–eNOS activation, FAK–paxillin-mediated cell migration and adhesion, growth hormone receptor upregulation in tendon fibroblasts with downstream JAK2 signalling, ERK1/2-driven granulation and re-epithelialisation, and reduced COX-2 expression with lower IL-6 and TNF-alpha — and reported no acute toxicity across any organ system at doses from 6 mcg/kg to 20 mg/kg in animals, while noting that no study has assessed human safety. Mechanistically, BPC-157 raises VEGFR2 expression without raising VEGF-A itself, which is the basis for the view that it amplifies existing repair signalling at damaged tissue rather than initiating it.

Human data comprises three small pilot studies. Lee and Burgess (2025) infused two healthy adults with up to 20 mg intravenously with no adverse events. Lee, Walker and Ayadi (2024) treated 12 women with interstitial cystitis by single intravesical dose, with complete symptom resolution in 10 of 12. A retrospective series of 16 patients with chronic knee pain given a single intraarticular injection reported significant relief in 14 of 16 lasting 6 to 12 months. A Phase I trial registered in 2015 enrolled 42 subjects but was cancelled without published results.

On oncological risk, a 2025 narrative review (McGuire et al., 2025) found that in tumour contexts in animal models BPC-157 inhibited uncontrolled proliferation and downregulated VEGF expression, appearing to counteract rather than support tumour-driven angiogenesis. The authors described human data as "exceedingly sparse" and concluded it remains investigational.

Pharmacokinetics: half-life under 30 minutes, hepatic metabolism, renal excretion, urinary detection up to 4 days (Wang et al., 2022). Regulatory position: not FDA-approved, WADA-prohibited under S0 since 2022, and classified as an FDA Category 2 bulk drug substance in 2023, excluding it from compounding.